Overall market sentiment has been high on Atea Pharmaceuticals Inc (AVIR) stock lately. AVIR receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.
Atea Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on AVIR!
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.
InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.
The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.
What's Happening With AVIR Stock Today?
Atea Pharmaceuticals Inc (AVIR) stock is down -0.72% while the S&P 500 is higher by 0.52% as of 9:35 AM on Thursday, Feb 1. AVIR has fallen -$0.03 from the previous closing price of $4.16 on volume of 0 shares. Over the past year the S&P 500 is higher by 19.48% while AVIR has fallen -10.80%. AVIR lost -$1.57 per share in the over the last 12 months.
To screen for more stocks like Atea Pharmaceuticals Inc click here.
More About Atea Pharmaceuticals Inc
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection. The company's medicinal chemistry, virology, and pharmacology expertise, bolstered by its collective experience in drug development, enables it to pioneer new advancements in antiviral science.
Click Here to get the full Stock Report for Atea Pharmaceuticals Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
